Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

511.85INR
22 May 2018
Change (% chg)

Rs11.00 (+2.20%)
Prev Close
Rs500.85
Open
Rs500.00
Day's High
Rs513.80
Day's Low
Rs498.05
Volume
785,298
Avg. Vol
856,041
52-wk High
Rs746.00
52-wk Low
Rs493.50

Latest Key Developments (Source: Significant Developments)

Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS - ‍ENTERED INTO EXCLUSIVE DEAL WITH SAM CHUN DANG PHARM.GLENMARK PHARMACEUTICALS SAYS PRODUCTS FROM AGREEMENT WILL BE DEVELOPED AND MANUFACTURED BY SCD IN SOUTH KOREA.GLENMARK PHARMACEUTICALS SAYS WILL SEEK ALL MARKET AUTHORIZATIONS AND COMMERCIALIZE PRODUCTS FROM AGREEMENT IN NORTH AMERICA.  Full Article

India's Glenmark Pharmaceuticals Dec-Qtr Consol Profit Falls 78 Pct
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Glenmark Pharmaceuticals Ltd ::DEC QUARTER CONSOL PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 4.77 BILLION RUPEES LAST YEAR.<<>> CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 2.34 BILLION RUPEES.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 22.04 BILLION RUPEES VERSUS 25.35 BILLION RUPEES LAST YEAR.SAYS US BUSINESS DEGREW BY 40.21 PERCENT TO 73.59 BILLION RUPEES DURING Q3.  Full Article

Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864.  Full Article

Ligand Pharma And Glenmark Pharma Enter Into License Agreement
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS.LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​.  Full Article

Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Glenmark Pharmaceuticals Ltd ::LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Norethindrone Acetate, Ethinyl Estradiol Tablets
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS USP AND FERROUS FUMARATE TABLETS.  Full Article

Glenmark Pharmaceuticals Meets Primary Clinical Endpoint In Phase 3 Study Of Ryaltris
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS MET ITS PRIMARY CLINICAL ENDPOINT IN A PHASE 3 STUDY EVALUATING SAFETY OF RYALTRIS.SAYS RYALTRIS IS AN INVESTIGATIONAL FIXED-DOSE COMBINATION NASAL SPRAY, IN PERENNIAL ALLERGIC RHINITIS.TO FILE FIRST NDA TO US FDA FOR RYALTRIS IN THE FIRST QUARTER OF CY 2018.  Full Article

Glenmark Pharma Says Closed DCP For Generic Seretide Accuhaler In Nordic Region​
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Glenmark Pharmaceuticals Ltd ::ANNOUNCES CLOSURE OF DECENTRALISED REGISTRATION PROCEDURE (DCP) FOR GENERIC SERETIDE ACCUHALER IN NORDIC REGION​.  Full Article

Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS SAYS ‍BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017.GLENMARK PHARMACEUTICALS LTD <<>> SAYS ‍U.S. FDA ISSUED 7 OBSERVATIONS VIA FORM 483​​.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for HAILEY Fe 1/20 tablets ​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Glenmark Pharmaceuticals Ltd :Gets ANDA approval for HAILEY Fe 1/20 tablets ​.  Full Article

BRIEF-Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris

* GLENMARK PHARMACEUTICALS - SUBMITTED NDA TO U.S. FDA FOR LEADING RESPIRATORY PIPELINE CANDIDATE RYALTRIS Source text for Eikon: Further company coverage: